MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of “Hold” from Analysts

MoonLake Immunotherapeutics (NASDAQ:MLTX) has been assigned a consensus recommendation of “Hold” from the sixteen analysts that are presently covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and seven have issued a buy rating on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $27.8462.

Several equities research analysts have recently weighed in on the stock. Royal Bank Of Canada increased their price objective on shares of MoonLake Immunotherapeutics from $12.00 to $13.00 and gave the stock a “sector perform” rating in a research report on Monday, March 2nd. Oppenheimer boosted their target price on shares of MoonLake Immunotherapeutics from $30.00 to $35.00 and gave the company an “outperform” rating in a report on Tuesday, February 24th. UBS Group set a $24.00 price target on shares of MoonLake Immunotherapeutics in a research report on Friday, January 9th. Needham & Company LLC increased their price target on MoonLake Immunotherapeutics from $20.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, February 23rd. Finally, Zacks Research raised MoonLake Immunotherapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th.

MoonLake Immunotherapeutics Price Performance

MoonLake Immunotherapeutics stock opened at $17.03 on Friday. The stock’s 50 day moving average is $16.42 and its 200 day moving average is $20.99. MoonLake Immunotherapeutics has a one year low of $5.95 and a one year high of $62.75. The firm has a market cap of $1.22 billion, a P/E ratio of -4.84 and a beta of 1.20. The company has a debt-to-equity ratio of 0.24, a current ratio of 9.27 and a quick ratio of 9.27.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its earnings results on Wednesday, February 25th. The company reported ($0.92) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.92). During the same quarter last year, the company posted ($0.72) EPS. As a group, research analysts expect that MoonLake Immunotherapeutics will post -1.79 EPS for the current year.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

A number of hedge funds have recently added to or reduced their stakes in MLTX. Principal Financial Group Inc. bought a new position in shares of MoonLake Immunotherapeutics during the 3rd quarter worth approximately $509,000. Decheng Capital LLC bought a new stake in shares of MoonLake Immunotherapeutics in the 2nd quarter valued at $8,572,000. Rhenman & Partners Asset Management AB lifted its position in shares of MoonLake Immunotherapeutics by 360.0% during the 3rd quarter. Rhenman & Partners Asset Management AB now owns 207,000 shares of the company’s stock valued at $1,484,000 after acquiring an additional 162,000 shares during the period. Hudson Bay Capital Management LP lifted its position in shares of MoonLake Immunotherapeutics by 31.3% during the 2nd quarter. Hudson Bay Capital Management LP now owns 105,000 shares of the company’s stock valued at $4,956,000 after acquiring an additional 25,000 shares during the period. Finally, Hood River Capital Management LLC boosted its stake in MoonLake Immunotherapeutics by 1.9% during the second quarter. Hood River Capital Management LLC now owns 675,445 shares of the company’s stock worth $31,881,000 after acquiring an additional 12,462 shares in the last quarter. 93.85% of the stock is currently owned by institutional investors.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.